Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03289065 · ClinicalTrials.gov registry record

Fabry Outcome Survey (FOS)

A clinical trial of Fabry Disease, sponsored by Shire.

Completed
Registry status
4,000
Enrollment target
1
Study location

NCT03289065: Completed study of Fabry Disease, sponsored by Shire.

NCT03289065 is a study of Fabry Disease that has completed, run by Shire. The registered enrollment target is 4,000 participants, above the 418-participant average among 32 other Fabry Disease trials with a reported enrollment target (857% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03289065, a study of Fabry Disease, has completed, sponsored by Shire.

COMPLETED
Registry status
4,000 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to collect data that will increase understanding of Fabry disease history and progression, in treated and untreated patients with Fabry disease. The data from FOS may provide guidance to healthcare professionals about disease treatment options.

Primary Outcome

An adverse event (AE) is any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in the registry, whether or not considered product-related. This includes an exacerbation of a pre-existing condition. An AE or ADR that meets one or more of the following criteria/outcomes is classified as SAE whether considered to be related to the pharmaceutical product or not: death, life-threatening

Conditions Studied

Fabry Disease

Study Locations (1)

Massachusetts

  • Shire - Lexington

Trial Details

FieldValue
Enrollment Target 4,000 participants
Start Date 2001-04-01
Est. Completion 2021-09-30
Shire

245 total trials

What the finished NCT03289065 record still lists

NCT03289065 is an observational study that tracks outcomes without assigning an intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, above the 418-participant average among 32 other Fabry Disease trials with a reported enrollment target (857% higher).

The record links to 1 condition, with Fabry Disease appearing as the primary indexed condition, and to 0 interventions.

NCT03289065 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03289065 about?

NCT03289065 is a clinical study titled "Fabry Outcome Survey (FOS)". The purpose of this study is to collect data that will increase understanding of Fabry disease history and progression, in treated and untreated patients with Fabry disease. The data from FOS may provide guidance to healthcare professionals about disease treatment options.

What is the current status of trial NCT03289065?

This trial is currently completed. The enrollment target is 4,000 participants. The study started on 2001-04-01. Estimated completion is 2021-09-30.

What conditions does trial NCT03289065 study?

This clinical trial studies the following conditions: Fabry Disease.

Who is sponsoring clinical trial NCT03289065?

This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03289065 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Fabry Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03289065's enrollment target sits among peer trials

4,000 2nd of 32 the highest of 32 other Fabry Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fabry Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00227253 · 4,000 participants

    Chromosome 18 Clinical Research Center

  • NCT00811148 · 4,000 participants

    Florida Center for Brain Tumor Research

  • NCT00897117 · 4,000 participants

    Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

  • NCT00899301 · 4,000 participants

    Collecting and Storing Tissue Samples From Women With or Without Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03289065, the US trial registry maintained by the National Library of Medicine. NCT03289065 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.